Search

Displaying results 2421 - 2430 of 7503 in total
  1. Drug

    Sebelipase alfa

    go.drugbank.com/drugs/DB11563
    ApprovedInvestigational

    It was first approved by both the FDA and EMA in 2015 and is marketed under the brand name Kanuma (Alexion Pharmaceuticals).[L39337,L39342] … This lipid accumulation can lead to end-organ damage in the form of liver dysfunction or malabsorption secondary to intestinal dysfunction.

  2. Drug

    Azatadine

    go.drugbank.com/drugs/DB00719
    ApprovedWithdrawn

    Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells.

    Mixtures: CO-TYLENOL
  3. Drug

    Lanolin alcohols

    go.drugbank.com/drugs/DB14181
    Approved

    Lanolin alcohols are a complex combination of organic alcohols obtained by the hydrolysis of lanolin. … It is administered as an ointment base with topical insulin and has shown to be antagonistic to wound healing. It is commonly used in allergenic testing.

  4. Drug

    Tiotropium

    go.drugbank.com/drugs/DB01409
    ApprovedInvestigational

    [A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation. … [A180163] Tiotropium was granted FDA approval on 30 January 2004.[L7084]

    Categories: Agents to Treat Airway Disease
  5. Drug

    Taletrectinib

    go.drugbank.com/drugs/DB18711
    ApprovedInvestigational

    [A274118] Taletrectinib was approved by the US FDA in June 2025 for use in patients with advanced ROS1-positive NSCLC.[L53308,L53523] … [L53308] Gene fusions involving _ROS1_, a proto-oncogene, have been identified as oncogenic drivers in 1-2% of patients with non-small cell lung cancer (NSCLC), in addition to other cancers at variable

  6. Drug

    Isoxicam

    go.drugbank.com/drugs/DB08942
    ApprovedWithdrawn

    Isoxicam is a non-steroidal anti-inflammatory drug that is not marketed in the United States.

    Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDS
  7. Drug

    Sitaxentan

    go.drugbank.com/drugs/DB06268
    ApprovedWithdrawn

    Sitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008.

  8. Drug

    Omidubicel

    go.drugbank.com/drugs/DB17132
    ApprovedInvestigational

    It is administered as a single intravenous dose specific to each patient. … In addition, the fact that 39% of the study's cohort were non-White patients highlights the importance of this type of treatment in key demographics with low donor availability.

  9. Drug

    Macimorelin

    go.drugbank.com/drugs/DB13074
    Approved

    Macimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution. … In addition, individuals with may be susceptible to cardiovascular complications from altered structures and function [A31484].

  10. Drug

    Desogestrel

    go.drugbank.com/drugs/DB00304
    ApprovedInvestigational

    [A176342] The first approved drug containing desogestrel was developed by Organon USA Inc in 1972 and FDA approved in 1992.[L5762] … [T521] Desogestrel is now produced semi-synthetically from naturally occurred plant steroids.[F4127] In the US, desogestrel is found only in combination with [ethinyl estradiol].

    Mixtures: O - ZETTE